Terms: = Prostate cancer AND ACVR2A, ACVR2, 92, ENSG00000121989, ACTRII, P27037 AND Clinical Outcome
38 results:
1. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
2. clinical outcome in metastatic prostate cancer after primary radiotherapy.
Moll M; Herrmann H; Zaharie A; Goldner G
Strahlenther Onkol; 2023 Jun; 199(6):536-543. PubMed ID: 35953611
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome of Salvage Radiotherapy for Locoregional clinical Recurrence After Radical prostatectomy.
Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR
Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469
[No Abstract] [Full Text] [Related]
4. Salvage Low-Dose-Rate prostate Brachytherapy: clinical outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).
Crook J; Rodgers JP; Pisansky TM; Trabulsi EJ; Amin MB; Bice W; Morton G; Murtha AD; Vigneault E; Helou J; Michalski JM; Roach M; Beyer D; Jani AB; Horwitz EM; Raben A; Pugh S; Sandler H
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1115-1122. PubMed ID: 34740768
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancer.
Moll M; Renner A; Kirisits C; Paschen C; Zaharie A; Goldner G
Strahlenther Onkol; 2021 Nov; 197(11):986-992. PubMed ID: 34351453
[TBL] [Abstract] [Full Text] [Related]
6. Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.
Hansum T; Hollemans E; Verhoef EI; Bangma CH; Rietbergen J; Osanto S; Pelger RCM; van Wezel T; van der Poel H; Bekers E; Helleman J; Remmers S; van Leenders GJLH
Mod Pathol; 2021 Nov; 34(11):2064-2070. PubMed ID: 34175896
[TBL] [Abstract] [Full Text] [Related]
7. Androgens and Overall Survival in Patients With Metastatic Castration-resistant prostate cancer Treated With Docetaxel.
Ryan CJ; Dutta S; Kelly WK; Middleberg R; Russell C; Morris MJ; Taplin ME; Halabi S;
Clin Genitourin Cancer; 2020 Jun; 18(3):222-229.e2. PubMed ID: 32273234
[TBL] [Abstract] [Full Text] [Related]
8. High efficacy of hypofractionated proton therapy with 4 fractions of 5 Gy as a boost to 50 Gy photon therapy for localized prostate cancer.
Johansson S; Isacsson U; Sandin F; Turesson I
Radiother Oncol; 2019 Dec; 141():164-173. PubMed ID: 31431382
[TBL] [Abstract] [Full Text] [Related]
9. Early Post-treatment prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced prostate cancer: An International Collaborative Analysis.
Rescigno P; Dolling D; Conteduca V; Rediti M; Bianchini D; Lolli C; Ong M; Li H; Omlin AG; Schmid S; Caffo O; Zivi A; Pezaro CJ; Morley C; Olmos D; Romero-Laorden N; Castro E; Saez MI; Mehra N; Smeenk S; Sideris S; Gil T; Banks P; Sandhu SK; Sternberg CN; De Giorgi U; De Bono JS
Eur Urol Oncol; 2020 Apr; 3(2):176-182. PubMed ID: 31307958
[TBL] [Abstract] [Full Text] [Related]
10. Improved survival for patients with prostate cancer receiving high-dose-rate brachytherapy boost to EBRT compared with EBRT alone.
Kent AR; Matheson B; Millar JL
Brachytherapy; 2019; 18(3):313-321. PubMed ID: 30846330
[TBL] [Abstract] [Full Text] [Related]
11. Overexpression of Periostin in Tumor Biopsy Samples Is Associated With prostate cancer Phenotype and clinical outcome.
Cattrini C; Rubagotti A; Nuzzo PV; Zinoli L; Salvi S; Boccardo S; Perachino M; Cerbone L; Vallome G; Latocca MM; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2018 Dec; 16(6):e1257-e1265. PubMed ID: 30170989
[TBL] [Abstract] [Full Text] [Related]
12. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
[TBL] [Abstract] [Full Text] [Related]
13. Assessment of radiobiological metrics applied to patient-specific QA process of VMAT prostate treatments.
Clemente-Gutiérrez F; Pérez-Vara C; Clavo-Herranz MH; López-Carrizosa C; Pérez-Regadera J; Ibáñez-Villoslada C
J Appl Clin Med Phys; 2016 Mar; 17(2):341-367. PubMed ID: 27074458
[TBL] [Abstract] [Full Text] [Related]
14. 4D Brachytherapy, a novel real-time prostate brachytherapy technique using stranded and loose seeds.
Langley SE; Laing RW
BJU Int; 2012 Feb; 109 Suppl 1():1-6. PubMed ID: 22239223
[TBL] [Abstract] [Full Text] [Related]
15. Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.
Feng FY; Qian Y; Stenmark MH; Halverson S; Blas K; Vance S; Sandler HM; Hamstra DA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e361-7. PubMed ID: 21820250
[TBL] [Abstract] [Full Text] [Related]
16. The usefulness of S100P, mesothelin, fascin, prostate stem cell antigen, and 14-3-3 sigma in diagnosing pancreatic adenocarcinoma in cytological specimens obtained by endoscopic ultrasound guided fine-needle aspiration.
Dim DC; Jiang F; Qiu Q; Li T; Darwin P; Rodgers WH; Peng HQ
Diagn Cytopathol; 2014 Mar; 42(3):193-9. PubMed ID: 21538952
[TBL] [Abstract] [Full Text] [Related]
17. Postoperative radiotherapy for localized prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months.
Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Araya M; Mukumoto N; Mitsumori M; Teshima T;
Anticancer Res; 2009 Nov; 29(11):4605-13. PubMed ID: 20032410
[TBL] [Abstract] [Full Text] [Related]
18. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
[TBL] [Abstract] [Full Text] [Related]
19. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population?
Pfitzenmaier J; Pritsch M; Haferkamp A; Jakobi H; Fritsch F; Gilfrich C; Djakovic N; Buse S; Pahernik S; Hohenfellner M
BJU Int; 2009 Apr; 103(7):877-82. PubMed ID: 19007372
[TBL] [Abstract] [Full Text] [Related]
20. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
Kollmeier MA; Zelefsky MJ
Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
[TBL] [Abstract] [Full Text] [Related]
[Next]
